Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02284893 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 461
- Enrollment target
- 20
- Study locations
NCT02284893: Completed Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
NCT02284893 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 461 participants, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02284893, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 461 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.
Conditions Studied
Interventions
- DRUG Sitagliptin
- DRUG Dapagliflozin
- DRUG Saxagliptin
- DRUG Placebo matching with Saxagliptin
- DRUG Placebo matching with Dapagliflozin
Study Locations (20)
California
- Research Site - Huntington Beach
- Research Site - Huntington Park
- Research Site - Lomita
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Norwalk
- Research Site - Paramount
- Research Site - Sacramento
- Research Site - Tarzana
- Research Site - Tustin
Florida
- Research Site - Coral Gables
- Research Site - Kissimmee
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
Arizona
- Research Site - Mesa
- Research Site - Mesa
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
Colorado
- Research Site - Golden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 461 participants |
| Start Date | 2014-09-09 |
| Est. Completion | 2016-09-20 |
| Phase | Phase 3 |
What the finished NCT02284893 record still lists
NCT02284893 is an interventional study that assigns participants to a tested intervention. The registered 461 participants enrollment target is mid-sized for trials with a published cap, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 5 interventions - of which Sitagliptin is the first listed.
NCT02284893 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02284893 about?
NCT02284893 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone". Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.
What is the current status of trial NCT02284893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2014-09-09. Estimated completion is 2016-09-20.
What conditions does trial NCT02284893 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT02284893?
The interventions under investigation include: Sitagliptin (DRUG), Dapagliflozin (DRUG), Saxagliptin (DRUG), Placebo matching with Saxagliptin (DRUG), Placebo matching with Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02284893?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02284893 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02284893's enrollment target sits among peer trials
461 46th of 327 higher than 282 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI